Non-steroidal anti-inflammatory drugs Market

Global Non-steroidal anti-inflammatory drugs Market Size, Share & Trends Analysis Report by Type (Oral, Parenteral) by Application (Arthritis, Migraine, Ophthalmic Diseases) by Distribution channel (Hospital Pharmacies, Retail Pharmacies, Others Distribution Channels) and Forecast (2020-2026)

Published: Oct 2021 | Report Code: OMR2024278 | Category : Pharmaceuticals | Delivery Format: /

The Global Non-steroidal anti-inflammatory drugs market is estimated to grow at a significant CAGR during the forecast period. FDA-approved antipyretic, anti-inflammatory, and analgesic drugs are known as nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are used to treat arthritic diseases, muscular pain, gout, dysmenorrhea pyrexia, migraines, and as opioid-sparing drugs in some acute trauma cases because of these effects.

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. The rising prevalence of ankylosing spondylitis, osteoarthritis, rheumatoid arthritis, migraine, and other immune disorders is driving up demand for these drugs. These have become the most widely prescribed drugs in the globe, as the number of prescriptions has increased. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen and diclofenac have been shown to be highly effective in suppressing the pain caused by osteoarthritis, and they can cause stomach pain, cardiovascular disorder, hemorrhage problems, and liver and kidney damage. NSAID gels have also been shown to relieve pain while having fewer adverse effects. Doctors are increasingly prescribing biologics, a new type of anti-inflammatory drug. Due to a rise in obesity, sedentary lifestyles and bad eating habits, the risk of arthritis has increased.

In the United States, over 84 million NSAID prescriptions are written each year, according to Endo International plc. This is expected to boost the market's growth. Furthermore, the Centers for Disease Control and Prevention's positive recommendations on the use of non-opioid drugs for the treatment of pain would aid the market's growth.

In May 2019, The FDA  had approved an Abbreviated New Drug Application (ANDA) for Voltaren Gel, according to Perrigo Company plc. This is likely to have a beneficial influence on the market for NSAIDs.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment covered

o By Type

o By Application 

o By distribution Channel

  • Region Covered

o Global

  • Competitive Landscape- Pfizer Inc., Amgen Inc., GlaxoSmithKline PLC., Johnson & Johnson., Novartis AG., and F. Hoffmann-La Roche AG., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Market Segmentation

Global Non-steroidal anti-inflammatory drugs market is segmented by Type

o Oral

o Parenteral

Global Non-steroidal anti-inflammatory drugs market is segmented by Application

o Arthritis

o Migraine

o Ophthalmic Diseases

o Other Applications

Global Non-steroidal anti-inflammatory drugs market by Distribution Channel

o Hospital Pharmacies

o Retail Pharmacies

o Others Distribution Channels

Global Non-steroidal anti-inflammatory drugs market is segmented by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa

REQUEST FOR TABLE OF CONTENT